H.C. Wainwright lowered the firm’s price target on Annovis Bio (ANVS) to $10 from $12 and keeps a Buy rating on the shares. The firm says the company’s buntanetap Alzheimer’s disease pivotal trial remains in progress. It cites a lengthier time to potential approval for the target cut.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANVS:
- Annovis Bio Reports Q2 2025 Progress and Financials
- Annovis Bio’s Promising Alzheimer’s Drug Trial: What Investors Need to Know
- Annovis Bio’s Strategic Advancements and Phase 3 Study Progress Support Buy Rating
- Annovis Bio completes full patent transfer to crystal buntanetap
- Annovis Bio Inc.’s Promising Alzheimer’s Drug Trial: Key Updates for Investors